Changes in lipoprotein kinetics associated with type 2 diabetes affect the distribution of lipopolysaccharides among lipoproteins

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 7, 2014, Pages

  Vergès, Bruno ^a,b   Duvillard, Laurence ^b   Lagrost, Laurent ^b   Vachoux, Christelle ^b   Garret, Céline ^b   Bouyer, Karine ^c   Courtney, Michael ^c   Pomié, Céline ^b   Burcelin, Rémy ^b  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c VAIOMER SAS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A5; APOLIPOPROTEIN B100; HIGH DENSITY LIPOPROTEIN; LIPOPOLYSACCHARIDE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CATABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; KINETICS; LIPOPOLYSACCHARIDES; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84904065906     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3463     Document Type: Article

References (40)

1. Wang X, Quinn PJ. Lipopolysaccharide: biosynthetic pathway and structure modification. Prog Lipid Res. 2010;49(2):97-107.
2. Harris RL, Musher DM, Bloom K, et al. Manifestations of sepsis. Arch Intern Med. 1987;147(11):1895-1906. (Pubitemid 18003345)
3. De Kimpe SJ, Kengatharan M, Thiemermann C, Vane JR. The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc Natl Acad Sci USA. 1995;92(22):10359-10363.
4. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-1772. (Pubitemid 47025442)
5. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57(6):1470-1481.
6. Koren O, Spor A, Felin J, et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci USA. 2011;108(suppl 1):4592-4598.
7. Amar J, Burcelin R, Ruidavets JB, et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr. 2008;87(5):1219-1223. (Pubitemid 351679761)
8. Van Lenten BJ, Fogelman AM, Haberland ME, Edwards PA. The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide. Proc Natl Acad Sci USA. 1986;83(8):2704-2708. (Pubitemid 16026952)
9. Barcia AM, Harris HW. Triglyceride-rich lipoproteins as agents of innate immunity. Clin Infect Dis. 2005;41(suppl 7):S498-S503. (Pubitemid 41598311)
10. Kitchens RL, Thompson PA, Viriyakosol S, O'Keefe GE, Munford RS. Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest. 2001;108(3):485-493. (Pubitemid 32730795)
11. Vreugdenhil ACE, Rousseau CH, Hartung T, Greve JWM, van 't Veer C, Buurman WA. Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. J Immunol. 2003;170(3):1399-1405. (Pubitemid 36139507)
12. Harris HW, Grunfeld C, Feingold KR, Rapp JH. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest. 1990;86(3):696-702. (Pubitemid 20327356)
13. Navab M, Hough GP, Van Lenten BJ, Berliner JA, Fogelman AM. Low density lipoproteins transfer bacterial lipopolysaccharides across endothelial monolayers in a biologically active form. J Clin Invest. 1988;81(2):601-605. (Pubitemid 18075257)
14. Ulevitch RJ, Johnston AR. The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum. J Clin Invest. 1978;62(6):1313-1324. (Pubitemid 9075761)
15. Ulevitch RJ, Johnston AR, Weinstein DB. New function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides. J Clin Invest. 1979;64(5):1516-1524.
16. Levels JHM, Abraham PR, van den Ende A, van Deventer SJH. Distribution and kinetics of lipoprotein-bound endotoxin. Infect Immun. 2001;69(5):2821-2828. (Pubitemid 32332170)
17. Eggesbø JB, Lyberg T, Aspelin T, Hjermann I, Kierulf P. Different binding of 125I-LPS to plasma proteins from persons with high or low HDL. Scand J Clin Lab Invest. 1996;56(6):533-543. (Pubitemid 26342638)
18. Vreugdenhil ACE, Snoek AMP, van 't Veer C, Greve J-WM, Buurman WA. LPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endotoxin-LDL/VLDL interaction. J Clin Invest. 2001;107(2):225-234. (Pubitemid 32096839)
19. Duvillard L, Pont F, Florentin E, Gambert P, Vergès B. Significant improvement of apolipoprotein B-containing lipoprotein metabolism by insulin treatment in patients with non-insulin-dependent diabetes mellitus. Diabetologia. 2000;43(1):27-35. (Pubitemid 30129299)
20. Pont F, Duvillard L, Maugeais C, et al. Isotope ratio mass spectrometry, compared with conventional mass spectrometry in kinetic studies at low and high enrichment levels: application to lipoprotein kinetics. Anal Biochem. 1997;248(2):277-287. (Pubitemid 27233165)
21. Taskinen MR, Packard CJ, Shepherd J. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Diabetes. 1990;39(9):1017-1027. (Pubitemid 20263310)
22. Millar JS, Maugeais C, Ikewaki K, et al. Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production. Arterioscler Thromb Vasc Biol. 2005;25(3):560-565. (Pubitemid 40315678)
23. Barrett PH, Bell BM, Cobelli C, et al. SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. Metab Clin Exp. 1998;47(4):484-492. (Pubitemid 28180958)
24. Tremblay AJ, Lamarche B, Cohn JS, Hogue J-C, Couture P. Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2006;26(5):1101-1106. (Pubitemid 43732118)
25. Welty FK, Lichtenstein AH, Barrett PH, Dolnikowski GG, Schaefer EJ. Human apolipoprotein (Apo) B-48 and ApoB-100 kinetics with stable isotopes. Arterioscler Thromb Vasc Biol. 1999;19(12):2966-2974. (Pubitemid 30029826)
26. Ikewaki K, Rader DJ, Schaefer JR, Fairwell T, Zech LA, Brewer HB Jr. Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods. J Lipid Res. 1993;34(12):2207-2215. (Pubitemid 24000968)
27. Pont F, Duvillard L, Vergès B, Gambert P. Development of compartmental models in stable-isotope experiments: application to lipid metabolism. Arterioscler Thromb Vasc Biol. 1998;18(6):853-860. (Pubitemid 28272577)
28. Cobelli C, Toffolo G, Foster DM. Tracer-to-tracee ratio for analysis of stable isotope tracer data: link with radioactive kinetic formalism. Am J Physiol. 1992;262(6 Pt 1):E968-E975.
29. Cummings MH, Watts GF, Pal C, et al. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in obesity: a stable isotope study. Clin Sci. 1995;88(2):225-233.
30. Pont F, Duvillard L, Florentin E, Gambert P, Vergès B. High-density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients. An in vivo stable isotope study. Int J Obes Relat Metab Disord. 2002;26(9):1151-1158.
31. Kashyap SR, Diab DL, Baker AR, et al. Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort. Obesity (Silver Spring). 2009;17(9):1696-1701.
32. Marçais C, Vergès B, Charrière S, et al. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest. 2005;115(10):2862-2869. (Pubitemid 41434413)
33. Vesy CJ, Kitchens RL, Wolfbauer G, Albers JJ, Munford RS. Lipopolysaccharide-binding protein and phospholipid transfer protein release lipopolysaccharides from Gram-negative bacterial membranes. Infect Immun. 2000;68(5):2410-2417. (Pubitemid 30253806)
34. Parhofer KG, Hugh P, Barrett R, Bier DM, Schonfeld G. Determination of kinetic parameters of apolipoprotein B metabolism using amino acids labeled with stable isotopes. J Lipid Res. 1991;32(8):1311-23.
35. Demant T, Packard CJ, Demmelmair H, Stewart P, Bedynek A, Bedford D, et al. Sensitive methods to study human apolipoprotein B metabolism using stable isotope-labeled amino acids. Am J Physiol. 1996;270(6 Pt 1):E1022-E1036.
36. Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis. 2001;33(8):1352-1357. (Pubitemid 32955186)
37. Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation. 2004;110(7):880-885. (Pubitemid 39096018)
38. Jones SP, Gibson MF, Rimmer DM III, Gibson TM, Sharp BR, Lefer DJ. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol. 2002;40(6):1172-1178.
39. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methyl-glutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21(11):1712-1719. (Pubitemid 34219772)
40. Calle MC, Fernandez ML. Inflammation and type 2 diabetes. Diabetes, Metabolism. 2012;38(3):183-191.